The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02704299|
Recruitment Status : Unknown
Verified March 2016 by Cellular Biomedicine Group Ltd..
Recruitment status was: Not yet recruiting
First Posted : March 10, 2016
Last Update Posted : March 11, 2016
|Condition or disease||Intervention/treatment||Phase|
|Gastric Cancer.||Biological: Autologous T cells-Based Immunotherapy||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.|
|Study Start Date :||March 2016|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||September 2018|
Experimental: Autologous T cells-Based Immunotherapy
Surgery Chemotherapy Autologous T cells-Based Immunotherapy
Biological: Autologous T cells-Based Immunotherapy
TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
Other Name: TCM
- Progression-Free-Survival(PFS) [ Time Frame: 24months ]The primary objective is to assess progression free survival (PFS).
- Incidences of adverse events or serious adverse events [ Time Frame: 24months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02704299
|Contact: Jiafu / Ji, Doctor|
|Principal Investigator:||/ / /, /|